Subscribe to RSS
DOI: 10.1055/s-0036-1593828
ST-segment Elevation Myocardial Infarction Resulting from Stent Thrombosis in Contemporary Real-World Practice
Publication History
Publication Date:
26 December 2016 (online)
![](https://www.thieme-connect.de/media/ija/201701/lookinside/thumbnails/10-1055-s-0036-1593828_160049-1.jpg)
Abstract
Stent thrombosis (ST) is a rare but devastating complication after percutaneous coronary intervention. Newer generation drug-eluting stents (DES) and newer antiplatelet therapies have been shown to decrease the incidence of ST, but we continue to observe ST-segment elevation myocardial infarction (STEMI) due to ST in contemporary practice. A retrospective analysis of 527 patients who presented with STEMI was performed; 57 patients (11%) with angiographically confirmed ST were compared with the patients with STEMI due to de novo lesion. The type of previous stent, the timing of ST, and the use of antiplatelet therapy were reviewed in patients with ST. Patients with ST had higher prevalence of comorbid conditions, such as hypertension, diabetes mellitus, and coronary artery disease, and had lower left ventricular ejection fraction (37 ± 5 vs. 44 ± 16%, p = 0.0011). There was no difference in in-hospital mortality (2 vs. 4%, p = 0.7082). ST was seen most commonly as “very late” (56%), and with previous second-generation DES (40%). Eighty-two percent of patients among early ST, compared with 22% of patients with very late ST were on dual antiplatelet therapy (DAPT). In 12% of patients, ST happened after DAPT was stopped by physician for procedures. ST is seen in a variety of clinical settings with the most common presentation being very late ST and in second-generation DES, which most likely represent the growing population with previous second-generation stents.
-
References
- 1 Iakovou I, Schmidt T, Bonizzoni E , et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293 (17) 2126-2130
- 2 Palmerini T, Kirtane AJ, Serruys PW , et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5 (3) 357-364
- 3 Wiviott SD, Braunwald E, McCabe CH , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
- 4 Wallentin L, Becker RC, Budaj A , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
- 5 Räber L, Magro M, Stefanini GG , et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125 (9) 1110-1121
- 6 Thygesen K, Alpert JS, Jaffe AS , et al; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60 (16) 1581-1598
- 7 Chechi T, Vecchio S, Vittori G , et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 2008; 51 (25) 2396-2402
- 8 Brodie BR, Hansen C, Garberich RF , et al. ST-segment elevation myocardial infarction resulting from stent thrombosis: an enlarging subgroup of high-risk patients. J Am Coll Cardiol 2012; 60 (19) 1989-1991
- 9 Ergelen M, Gorgulu S, Uyarel H , et al. The outcome of primary percutaneous coronary intervention for stent thrombosis causing ST-elevation myocardial infarction. Am Heart J 2010; 159 (4) 672-676
- 10 Parodi G, Memisha G, Bellandi B , et al. Effectiveness of primary percutaneous coronary interventions for stent thrombosis. Am J Cardiol 2009; 103 (7) 913-916
- 11 Armstrong EJ, Feldman DN, Wang TY , et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012; 5 (2) 131-140
- 12 Secemsky EA, Matteau A, Yeh RW , et al; PROTECT Trial Investigators. Comparison of short- and long-term cardiac mortality in early versus late stent thrombosis (from Pooled PROTECT Trials). Am J Cardiol 2015; 115 (12) 1678-1684
- 13 van Werkum JW, Heestermans AA, Zomer AC , et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53 (16) 1399-1409
- 14 Yeo KK, Mahmud E, Armstrong EJ , et al. Contemporary clinical characteristics, treatment, and outcomes of angiographically confirmed coronary stent thrombosis: results from a multicenter California registry. Catheter Cardiovasc Interv 2012; 79 (4) 550-556
- 15 Tada T, Byrne RA, Simunovic I , et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013; 6 (12) 1267-1274
- 16 Waksman R, Kirtane AJ, Torguson R , et al; DESERT Investigators. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis). JACC Cardiovasc Interv 2014; 7 (10) 1093-1102
- 17 Kang SJ, Lee CW, Song H , et al. OCT analysis in patients with very late stent thrombosis. JACC Cardiovasc Imaging 2013; 6 (6) 695-703
- 18 Levine GN, Bates ER, Blankenship JC , et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58 (24) e44-e122
- 19 Mauri L, Kereiakes DJ, Yeh RW , et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371 (23) 2155-2166
- 20 Mehran R, Baber U, Steg PG , et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382 (9906): 1714-1722